Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coradini, D.
Right arrow Articles by Perbellini, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coradini, D.
Right arrow Articles by Perbellini, A.
Clinical Cancer Research Vol. 10, 4822-4830, July 15, 2004
© 2004 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Inhibition of Hepatocellular Carcinomas in vitro and Hepatic Metastases in vivo in Mice by the Histone Deacetylase Inhibitor HA-But

Danila Coradini1, Sonia Zorzet2, Raffaella Rossin3, Ignazio Scarlata4, Cinzia Pellizzaro1, Claudia Turrin5, Michele Bello6, Silvia Cantoni4, Annalisa Speranza1, Gianni Sava2, Ulderico Mazzi3 and Alberto Perbellini7

1 Unit of Biomolecular Determinants in Prognosis and Therapy, Experimental Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan; 2 Department of Biomedical Sciences, University of Trieste, Trieste; 3 Department of Pharmaceutical Sciences, University of Padova, Padova; 4 Biochemistry, Biophysics, and Chemistry of Macromolecules Department, University of Trieste, Trieste; 5 Callerio Onlus Foundation, Trieste; 6 Istituto Nazionale Fisica Nucleare-Laboratorio Nazionale Legnaro, Legnaro, Padova; and 7 Coimex S.c.r.l., Reggio Emilia, Italy


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 
Purpose: The purpose is to evaluate the CD44-mediated cellular targeting of HA-But, a hyaluronic acid esterified with butyric acid (But) residues, to hepatocellular carcinoma cell lines in vitro and to hepatic tumor metastases in vivo.

Experimental Design: In vitro, the CD44-dependent cytotoxicity in two human hepatocellular carcinoma cell lines (HepB3 and HepG2) with high and low CD44 expression was investigated; in vivo, the effect on liver metastases originating from intrasplenic implants of Lewis lung carcinoma (LL3) or B16-F10 melanoma in mice was compared with the pharmacokinetics of organ and tissue distribution using different routes of administration.

Results: HepB3 and HepG2 cell lines showed different expression of CD44 (78 and 18%, respectively), which resulted in a CD44-dependent HA-But inhibitory effect as demonstrated also by the uptake analysis performed using radiolabeled HA-But (99mTc-HA-But). Pharmacokinetic studies showed different rates of 99mTc-HA-But distribution according to the route of administration (i.v., i.p., or s.c.): very fast (a few minutes) after i.v. treatment, with substantial accumulation in the liver and spleen; relatively slow after i.p. or s.c. treatment, with marked persistence of the drug at the site of injection. The effect of s.c. and i.p. treatment with HA-But on liver metastases originating from intrasplenic implants of LL3 carcinoma or B16-F10 melanoma (both CD44-positive: 68 and 87%, respectively), resulted in 87 and 100% metastases-free animals, respectively (regardless of the route of administration), and a significant prolongation of the life expectancy compared with control groups.

Conclusions: HA-But tends to concentrate in the liver and spleen and appears to be a promising new drug for the treatment of intrahepatic tumor lesions.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 
Liver cancer, in particular hepatocellular carcinoma, is one of the most common fatal cancers in the world (1) . In addition to harboring primary tumors, the liver is often the target organ for metastatic lesions from colon (2) , breast (3) , or lung cancers (4) . Unfortunately, treatment failure is frequent and results in high recurrence rates with short survival times (5, 6, 7) . Histone deacetylase inhibitors (HDACi), including sodium butyrate, are potent inducers of cell growth arrest, differentiation, or apoptosis in a variety of transformed cell lines, including hepatocellular carcinoma, and in intrahepatic metastasis-bearing animals (8 , 9) . Their mechanism of action is based on their ability to inhibit the activity of histone deacetylase enzymes (HDACs); these enzymes, as opposed to histone acetyltransferases, are involved in the regulation of gene expression by determining the degree of acetylation of histones, the core proteins of the nucleosomal structure. HDAC inhibition results in reactivation of the expression of several genes, including those responsible for cell growth control and differentiation. On this basis, HDACi represent a class of potentially effective anticancer agents (10) .

Because a major challenge in cancer therapy is to selectively target cytotoxic agents to tumor cells and at the same time reduce the side effects of these agents, we developed HA-But, a new chemical entity constituted by a backbone of hyaluronic acid (HA) partially esterified with butyric acid (But), the smallest HDACi (11) . One of the main characteristics of HA-But is its strong affinity for CD44 (12) , the specific membrane receptor for HA, which is overexpressed in most human cancers, including liver carcinoma (13) .

In the present study, we investigated the in vitro effect of HA-But on the growth of two human hepatocellular carcinoma cell lines, HepB3 and HepG2. Because the presence of CD44 receptors is a fundamental requirement for the effectiveness of HA-But, we also verified the CD44 status of the two cell lines by conventional flow cytometric analysis and using technetium-99m (99mTc)-labeled HA-But for functional analysis. 99mTc, chosen for its optimal nuclear properties (14) , was directly anchored to the HA polymer (15) , thus obtaining stable labeled species (99mTc-HA and 99mTc-HA-But) suitable for in vitro receptor binding experiments and for pharmacokinetic studies aimed at investigating the in vivo distribution of HA-But. Furthermore, we investigated in vivo the ability of HA-But to inhibit the development of liver metastases in mice bearing intrasplenic implants of Lewis lung carcinoma (LL3; Ref. 16 ) or B16-F10 melanoma (17) and to improve their overall survival.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS AND DISCUSSION
 REFERENCES
 
Chemistry.
HA-But, characterized by a 0.06 degree of substitution (the ratio between the number of substituted hydroxyl groups and the number of the repeating disaccharide units of polysaccharide), was prepared as described elsewhere (11) . Briefly, the esterification reaction was accomplished by means of an activated reactive form of But, i.e., an adduct between butyric anhydride and 4-dimethylaminopyridine. Before any biological evaluation, the compound was purified by preparative thin layer liquid chromatography, its structure was determined by 1H NMR spectroscopy, and the degree of substitution of the ester measured by capillary electrophoresis in terms of free But residues delivered from the ester by basic hydrolysis. The samples used were estimated to be at least 95% pure.

Cell Lines and Cell Growth Inhibition.
The human hepatocellular carcinoma cell lines HepG2 and HepB3 were purchased from the American Tissue Culture Collection (Manassas, VA) and were maintained in Eagle’s minimum essential medium supplemented with 10% fetal bovine serum (v/v), 1% glutamine (v/v), 1% sodium pyruvate (v/v), and 1% of nonessential amino acids (v/v) in T-75-cm2 plastic flasks at 37°C in a 5% CO2-humidified atmosphere and passaged weekly. Before the start of the experiments, cells in the exponential growth phase were removed from the flasks with a 0.05% trypsin-0.02% EDTA solution. Mycoplasma-free cells were seeded in 96-wells/plates (1000 cells/200 µl/well for both cell lines) in Eagle’s minimum essential medium supplemented with 10% fetal bovine serum (v/v), 1% glutamine (v/v), 1% sodium pyruvate (v/v), and 1% of nonessential amino acids (v/v). The cells were allowed to adhere for 24 h; the seeding medium was removed and replaced with experimental medium. Cells were kept for 6 days, an interval sufficient to observe a statistically significant difference with respect to control, in the medium supplemented with increasing concentrations of HA (range: 0.016–4 mg/ml), HA-But (range: 0.016–4 mg/ml), or sodium butyrate (range: 0.016–4 mM). Experiments were performed at least twice and samples were run in eight replicates. At the end of the experiments the antiproliferative effect was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method. Formazan precipitates were dissolved in DMSO, and correspondent absorbance was measured at 540 nm using an ELx800 photometer. Wells containing all admixtures except cells were used as blanks, and IC50 was defined as the concentration of drug that inhibits cell growth, by 50% of the control.

Mice.
C57BL/6 and C57BL/6xDBA/2F1 (BD2F1) and CBA/Lac mice (Harlan & Nossan; San Giovanni al Natisone, Udine, Italy), 3–6 months old and weighing 18–20 g, were used in the experiments. The mice were bred and kept in the local animal facility. Animal experimentation was carried out according to the guidelines currently in force in Italy (DDL 116) and in compliance with the Guide for the Care and Use of Laboratory Animals.

In vivo Tumor Models.
The Lewis lung carcinoma (LL3) line was originally obtained from the Tumor Depository Bank, National Cancer Institute, NIH (Bethesda, MD), and was maintained by serial biweekly passages according to the National Cancer Institute protocols. Briefly, 1 x 106 viable tumor cells of a single suspension, prepared by mincing with scissors the primary tumors from donors similarly implanted 2 weeks previously, were injected i.m. into the left calf of female C57BL/6 mice. The minced tissue was filtered through a double layer of sterile gauze, centrifuged at 200 x g for 10 min, and resuspended in an equal volume of sterile PBS; viable cells were counted by the Trypan Blue exclusion test.

B16-F10 melanoma cells, originally obtained from the Tumor Depository Bank, National Cancer Institute, NIH, were cultured in modified Eagle’s medium supplemented with 10% FBS, 1% nonessential amino acids, 1% sodium pyruvate, 1% L-glutamine (100x), 1% standard antibiotics (all from Euroclone), 2% NaHCO3, and 1% glucose. Cells were maintained in a humidified 5% CO2 atmosphere at 37°C.

Flow Cytometric Analysis.
The expression of CD44 receptors was investigated by flow cytometry using a murine monoclonal antibody raised against human CD44 (clone 5F12; Neo Markers, Labvision, Fremont, CA) for HepG2 and HepB3 human cell lines or a rat antimouse CD44-FITC monoclonal antibody (2 µg; SouthernBiotech Associates, Inc., Birmingham, AL) for B16-F10 and 3LL murine cell lines. Cells were recovered from the flasks with trypsin-EDTA solution, washed with PBS, and centrifuged at 800 x g for 5 min. Parallel samples (1 x 106 cells each) were loaded, and cells were incubated with primary antibody at a dilution of 1:20 for 60 min at room temperature. The cells were then washed with PBS, centrifuged, and incubated with a secondary FITC-conjugated goat antimouse antibody (Sigma, St. Louis, MO) at a dilution of 1:50 for 30 min at room temperature in the dark. The negative control sample was incubated with the secondary antibody alone. After immunofluorescence staining, the cells were centrifuged and resuspended in a solution containing propidium iodide (5 (g/ml), RNase (10 kU/ml; Sigma), and NP40 (0.005%). The fluorescence of stained cells was measured using a FACScan flow cytometer (Becton Dickinson, San Jose, CA) equipped with an argon laser at 488 nm wavelength excitation and a 610-nm filter for propidium iodide fluorescence detection. The fluorescence signal was collected in linear and logarithmic mode. Data were acquired and processed using the LYSIS II software (Becton Dickinson); at least 30,000 events were recorded for each sample.

Direct Labeling of HA and HA-But with 99mTc.
HA and HA-But were labeled with 99mTc, the most widely used {gamma}-emitting radioisotope for radiodiagnostic purposes. Because of its optimal nuclear properties (E = 140 keV, T1/2 = 6.02 h), which allow efficient detection by means of gamma cameras (18) , 99mTc has recently been used as a radioactive probe also in pharmacological studies to investigate the in vivo distribution of new drugs (19 , 20) . When the target molecule is a high molecular weight homopolymer, 99mTc labeling leads to minor changes in charge, conformation, and hydrophilicity, without significant changes in biodistribution and physiological interactions. Because HA and HA-But contain many functional groups, useful to bind the 99mTc(V)oxo core (carboxylic, hydroxylic, and amino groups), a direct method to label the two polymeric species with 99mTc was applied (14 , 21) . Briefly, 99mTc-pertechnetate, freshly eluted from a 99Mo/ 99mTc generator (Nycomed-Amersham-Sorin, Saluggia, Italy), was reduced with 1 µl of a 0.1 M SnCl2 solution (in 0.1 M HCl) in the presence of sodium gluconate (1 µl of a 10-2 M solution) as exchange ligand. The polymeric species (3 mg) was then added, the pH was adjusted to 4.0 with 10-2 M HCl, and the labeling mixture was gently mixed at 50°C for 1.5 h. All radioactivity measurements were carried out using a Dose Calibrator (M2316 Messelektronik; Dresden). Labeling yield determination and 99mTc-polymeric species purification were performed by size exclusion chromatography, using a Hi-Trap desalting column (void volume 1.5 ml, Supelco; Sigma-Aldrich) with a 1000–5000 Da cutoff. 99mTc-HA and 99mTc-HA-But were eluted from the column with water while the Sephadex G25 resin retained 99mTc-pertechnetate and other low-weight species. The optimization of the 99mTc-labeling conditions for HA and HA-But has been reported elsewhere (15) . After this protocol, 85–95% labeling yields were obtained. The time stability of 99mTc-HA-But was investigated both as crude labeling mixture and in the presence of rat serum (200 µl of the polymer labeling mixture added to 400 µl of fresh serum). In both cases, the mixtures were incubated at 37°C, and the residual 99mTc-pertechnetate percentage was monitored for 6 h by size exclusion chromatography. No 99mTc-pertechnetate formation was observed during this interval, confirming that the metal-polymer complex was sufficiently stable to perform in vitro and in vivo experiments. For the evaluation of cellular uptake and in vivo distribution, native HA-But was added to the purified 99mTc-HA-But solution to a final concentration of 5 and 30 mg/ml, respectively.

Cellular Uptake of 99mTc-HA-But.
HepG2 and HepB3 cells were seeded in chamber slides (5 x 105 cells/chamber) in Eagle’s minimum essential medium supplemented with 10% fetal bovine serum (v/v), 1% glutamine (v/v), 1% sodium pyruvate (v/v), and 1% of nonessential amino acids (v/v). The cells were grown at 37°C in a 5% CO2-humidified atmosphere until they reached the exponential growth phase. Before the binding experiments were started, the seeding medium was removed, and cells were washed twice with PBS solution. Purified 99mTc-HA-But was diluted with native cold polymer to obtain a 5 mg/ml concentration, and 2 ml of this experimental medium (50 MBq) were then added to the chamber, slides and cells were incubated for 0.5, 1, 2, 3, 4, 5, and 6 h at 37°C. After incubation, the cells were abundantly washed with PBS, and residual bound radioactivity was measured and corrected for nonspecific binding (background). To evaluate the specific uptake of HA on CD44 receptors, in a parallel series of experiments, the cells were pretreated for 4 h at 37°C with a 10-fold concentrated HA solution (50 mg/ml) before addition of 99mTc-HA.

Yttrium-Aluminum-Perovskite (YAP) Camera for Biodistribution Studies.
The YAP camera (see Fig. 3ACitation ) is a gamma camera with a high spatial resolution used for biodistribution studies in small animals (18 , 19) . It is based on a segmented crystal scintillator (YAlO3, Perovskite crystal doped with 0.2% Ce3+ ions) optically coupled to a positron-sensitive photomultiplier, and it was designed at the Physics Department of the University "La Sapienza," Rome. A 40 x 40-mm2-view field, suitable for mice imaging, characterizes this camera. Scintigraphic images were elaborated by a dedicated software connected to the hardware as described elsewhere (18) . In vivo distribution of 99mTc-HA-But was evaluated in healthy male CBA/Lac mice after i.v., s.c., or i.p. administration. Briefly, mice previously anesthetized with ketamine hydrochloride (125 mg/kg, i.p.) were injected i.v., s.c. (at two abdominal sites), or i.p. with 200 µl, 2 x 250 µl or 250 µl of a HA-But saline solution containing 99mTc-HA-But (13, 148, and 12 MBq, respectively). Scintigraphic images of the mice’s abdomens were collected by the YAP camera for 1 h after i.v. injection, for 6 h after s.c. administration, and for 3 h after i.p. injection. At the end of image collection, the animals were sacrificed, the ex vivo distribution was evaluated, and organ radioactivity accumulation was measured.



View larger version (64K):
[in this window]
[in a new window]
  		Fig. 3. In vivo distribution of 99mTc HA-But was investigated using a yttrium-aluminum-perovskite camera (A), a high-spatial resolution gamma camera. B and C show the scintigraphic images of mouse abdomens obtained 1 h after i.v. (B) or 6 h after s.c. (C) administration of a HA-But saline solution containing 99mTc-HA-But. Arrows indicate the main sites of accumulation: 46% of the injected dose in the liver after i.v. administration and 36% of the injected dose at the site of injection after s.c. administration.

 
Intrasplenic Implantation and Liver Metastasis Counting.
Intrasplenic injection of tumor cells was performed in a UV sterile fume hood. Thirty-two female BD2F1 mice were anesthetized with an i.p. injection of 70 mg/kg Zoletil (Virbac srl, Milan, Italy), and their spleens were exposed through a small left flank incision, then 2 x 105 viable LL3 carcinoma cells/50 µl Matrigel (150 µg/ml; Becton Dickinson) or 1 x 105 B16-F10 melanoma cells/50 µl Matrigel were implanted. Liver metastases were allowed to grow for 4 days, then groups of eight animals were treated i.p. or s.c. with 0.6 µmol (250 µl/mouse) HA-But, a dose free of toxicity in mice as demonstrated by separate experiments with both acute and chronic treatment (data not shown); the mice were treated daily until day 10. Control animals were treated i.p. or s.c. with an equal volume of 0.9% NaCl. On day 15 (LL3) or day 21 (B16-F10) after intrasplenic cell implantation, control and treated animals were sacrificed, and the formation of liver metastases was assessed as the number of neoplastic lesions counted by a low-power stereo microscope.

Histological Evaluation.
To evaluate the incidental effect of HA-But on the morphology of the liver parenchyma, livers of control and treated groups were removed, fixed in 10% formalin, and embedded in paraffin. Four-µm sections were stained by Cajal-Gallego procedure, a triple staining method that facilitated the identification of hepatocyte nucleus/cytoplasm and extracellular matrix, and the liver morphology was microscopically evaluated.

Survival Evaluation.
The effects of HA-But on the life expectancy of tumor-bearing animals was investigated in a parallel series of experiments in which female BD2F1 mice that had been intrasplenically implanted with 1 x 105 B16-F10 melanoma cells were s.c. injected with 0.15 µmol (125 µl/mouse/day) HA-But starting on day 4 and continuing until day 32 (the time at which the first control animal died), with an additional i.p. administration (12 µmol/mouse) on days 4, 11, 18, 25, and 31. The survival of the animals was recorded up to the death of the last animal.

Statistical Analysis.
Experimental data were subjected to computer-assisted statistical analysis, and the statistical significance of differences between IC50 values in the different cell lines was assessed by the two-tailed Student’s t test, whereas the effect of HA-But on the formation of metastases was evaluated by Fisher’s exact test. Overall survival was evaluated by Kaplan-Meier product limit survival analysis and the log rank test. Two-sided P values < 0.05 were considered statistically significant.


   RESULTS AND DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
REFERENCES
 
Cell Surface Expression of CD44, Cellular Uptake of 99mTc-HA-But, and Cell Growth Inhibition.
Flow cytometric analysis showed that only 18% of HepG2 cells expressed CD44 receptors on their surface, whereas 78% of HepB3 cells were CD44 positive (Fig. 1A)Citation . As shown in Fig. 1BCitation , time course experiments using the radiolabeled compound indicated that the two cell lines had different binding capability: the HepB3 binding activity increased in a time-dependent manner and reached a plateau ~6 h after treatment, whereas HepG2 had limited binding activity that started to decrease already after 4 h. Notwithstanding the presence of a different CD44 expression, HA-But was able to inhibit cell proliferation in both cell lines. In fact, as shown in Fig. 2Citation (top panels, as a function of mM butyric concentration; bottom panels, as a function of mg/ml concentration), after 6 days of treatment, it had a dose-dependent inhibitory effect: in HepB3 cells, at the highest concentration evaluated (4 mg/ml corresponding to 1 mM butyric concentration), HA-But induced almost complete inhibition of cell growth (90%), whereas in the CD44-poor HepG2 cells, moderate inhibition (60%) was observed, suggesting that after a sufficiently prolonged treatment interval (in this case 6 days), HA-But was effective also in CD44-poor tumor cells. A possible explanation could be the very rapid turnover of the CD44 receptor after HA-But uptake, which guarantees a continuous inhibitory intracellular concentration of the drug as demonstrated in a previous study (12) . However, even if CD44 is the major receptor for HA, other membrane receptors, including the receptor for hyaluronate-mediated mobility, could be responsible for HA-But internalization. Interestingly, HA-But was more effective than NaB alone, with a 10-fold decrease in the IC50 value (2.1 versus 0.12 mM and 3 versus 0.31 mM, P < 0.01, in HepG2 and HepB3 cells, respectively), which would suggest that the use of HA as a carrier for sodium butyrate can significantly improve its biological activity without any apparent negative effects due to the large dimension of the molecule.



View larger version (23K):
[in this window]
[in a new window]
  		Fig. 1. Cell surface expression of CD44 and cellular uptake of 99mTc-HA-But. The cell surface expression of CD44 of both hepatocellular carcinoma cell lines (A) was evaluated by flow cytometric analysis. HepG2 and HepB3 cells (1 x 106) were first incubated with a murine antihuman monoclonal antibody raised against human CD44 and then with goat FITC-labeled antimouse secondary antibody. Negative control ({blacksquare}) and stained samples ({square}) are shown. For time course, cellular 99mTc-HA-But uptake evaluation HepG2 and HepB3 cells were seeded in chamber slides (5 x 105 cells/chamber) and grown until the exponential phase (B). Purified 99mTc-HA-But, diluted with native cold polymer to obtain a 5 mg/ml concentration, was then added and cells were incubated for 6 h at 37°C.

 


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 2. Dose-effect curve of a 6-day treatment with Ha-But ({blacksquare}) and NaB (top panels) or hyaluronic acid (HA) (bottom panels; •) on the proliferation of HepG2 and HepB3 cell lines. In both cell lines, HA-But was more effective than the active principle, with a 10-fold decrease in IC50 (2.1 versus 0.12 mM for HepG2 and 3 versus 0.31 nM for HepB3).

 
In vivo Distribution of 99mTc HA-But.
An efficient 99mTc-labeling method (85–95% labeling yield) allowed us to obtain a very stable 99mTc-HA-But complex in which the partial functionalization of hydroxyl groups with butyl ester residues did not significantly influence the labeling yield. In vivo analysis of the HA-But distribution was performed by administering i.v., s.c., or i.p. a solution containing 99mTc-HA-But to healthy anesthetized male CBA/Lac mice. With regard to i.v. injection, the scintigraphic images, at any time and with a 10-min acquisition by the YAP camera (Fig. 3B)Citation , showed a very rapid and relevant liver uptake of radiolabeled HA-But uniformly distributed in both lobes. Uptake was visible after a few minutes and more intense after 1 h (Fig. 3B)Citation ; partial accumulation of the compound was seen in the kidneys, probably related to excretion of the fragments produced by polymer degradation. The result was confirmed by the postimaging distribution evaluation, which showed the liver to be the organ of preferential accumulation (46.52% of the injected dose). This is in agreement with the findings reported by Gustafson et al. (22) , who observed a similar distribution for the native HA. It is also in agreement with the observation that circulating HA is physiologically degraded by hepatic sinusoidal endothelial cells via the CD44 receptor (23) . Postimaging analysis indicated noticeable 99mT-HA-But accumulation also in the spleen, as expected given the role of the spleen in HA degradation (24) . In fact, considering the amount of 99mT-HA-But accumulated/g of tissue (expressed as percentage of the injected dose/g tissue, %ID/g) and thus taking into account the size of each organ, the spleen accumulated 11.66%ID/g, an amount consistent with that found in the liver, which accumulated 15.83%ID/g.

The high liver uptake observed after i.v. injection decreased considerably when 99mT-HA-But was given i.p. or s.c. Intraperitoneal administration reduced 99mTc HA-But accumulation in the liver to 12.33%ID/g, which additionally decreased to 0.47%ID/g after s.c. administration. Interestingly, after i.p. injection splenic accumulation of 99mTc HA-But was similar to that following i.v. administration (11.08%ID/g), whereas the liver uptake was reduced to 5.21%ID/g. This would imply that additional studies are necessary to evaluate the possible activity of HA-But in hyperproliferative diseases of the spleen. Lastly, scintigraphic images collected 6 h after s.c. administration showed that 36%ID/g 99mTc HA-But was still localized at the site of injection (Fig. 3C)Citation . Differences in HA-But pharmacokinetics depending on the route of administration could be exploited to appropriately target the drug: the i.v. route could be used for treating intrahepatic lesions, whereas the s.c. route might be more useful for treating local or splenic lesions or even to partially bypass the hepatic drug segregation. Mahteme et al. (25) demonstrated that the normal/tumor ratio HA distribution decreased by pretreating the animals with chondroitin sulfate due to the saturation of the normal hepatic sinusoidal cells. This observation supports our finding in a similar study (data not shown) where we demonstrated a different organ distribution of HA-But when drug administration was preceded by presaturation with chondroitin sulfate and suggests that it may be possible to treat not only hepatic lesions but also tumors in other organs.

HA-But Inhibits Formation of Liver Metastases.
Most of the available in vivo experimental models of liver metastases imply the production of artificial liver colonization via i.v.-injected tumor cells. To use an in vivo model more similar to the biological outcome of liver metastases, we chose to intrasplenically implant experimental tumor cells. We used LL3 carcinoma and B16-F10 melanoma cells, two murine tumors that had previously been shown to produce liver metastases after intrasplenic injection (26 , 27) and that expressed a high percentage of CD44-positive cells (68 and 87%, respectively; Fig. 4Citation ), in agreement with the recent finding by Mummert et al. (28) . The effect of 7-day i.p. or s.c. administration of 0.6 µmol of HA-But (a nontoxic dose to the host, as demonstrated in separate studies) on the formation of liver metastases is reported in Table 1Citation . HA-But reduced liver colonization, with a statistically significant difference compared with the control group (P < 0.05). In particular, when LL3 cells were considered, six of seven (86%) of the s.c.-treated animals and seven of eight (87.5%) of the i.p.-treated animals were free of macroscopically detectable metastases, and only one animal/treatment group (i.p. or s.c.) presented metastatic foci at sacrifice (i.e., 15 days after implantation). Conversely, in the untreated control group only one of seven (14%) of the s.c.-treated animals and one of eight (12.5%) of the i.p.-treated animals were metastases free (Table 1)Citation . A similar response rate was observed in mice that were intrasplenically implanted with B16-F10 melanoma cells; at sacrifice, all s.c. or i.p. HA-But-treated animals were free of macroscopically detectable liver metastases versus zero of seven animals in both (s.c. and i.p.) control groups. Histological analysis of the liver parenchyma indicated that, independent of the tumor type used, HA-But did not affect liver morphology (Fig. 5)Citation . This result appears even more interesting when we consider that HA-But very effectively inhibited liver metastasis formation, although it was not administered via the optimal route (i.v.).



View larger version (13K):
[in this window]
[in a new window]
  		Fig. 4. Cell surface expression of CD44, evaluated by flow cytometry, of B16-F10 and 3LL cells used in in vivo experimental model.

 

View this table:
[in this window]
[in a new window]
  		Table 1 Effect of 7-day i.p. or s.c. treatment with HA-But on liver metastasis formation after intrasplenic implantation of LL3 carcinoma or B16-F10 melanoma cells

 


View larger version (134K):
[in this window]
[in a new window]
  		Fig. 5. Representative photographs and microscope sections of the livers of animals that received intrasplenic implants of B16-F10 or LL3 cells and were treated or not with HA-But. Arrows indicate macroscopically detectable liver metastases. For histological evaluation, 4-µm sections from formalin-fixed and paraffin-embedded livers obtained from each treatment group were stained with Cajal-Gallego method and examined. No signs of liver damage due to HA-But treatment were observed.

 
Increased Life Expectancy in Animals Treated with HA-But.
For this experiment, we used the B16-F10 melanoma model because of the better results obtained in previous tests and of the very high CD44 positivity of these tumor cells. Prolonged treatment with HA-But for up to 12 days with low doses of HA-But significantly (P < 0.03) increased the life expectancy of BD2F1 mice over untreated controls (Kaplan-Meier analysis; Fig. 6Citation ). In addition, 90 days after tumor implantation, 8 of 10 HA-But treated animals were still alive versus 3 of 11 (27%) in the untreated group.



View larger version (11K):
[in this window]
[in a new window]
  		Fig. 6. Kaplan-Meier survival analysis of mice intrasplenically implanted with B16-F10 cells and treated or not with HA-But. At 90 days of follow-up, 8 of 10 treated animals compared with 3 of 11 control animals were still alive.

 
In conclusion, the present results indicate that HA-But, a compound in which HA is esterified with butyric ester and which has been previously reported to block lung cancer growth and spread (11) , could be useful also for the selective treatment of intrahepatic lesions. Undoubtedly, the use of HDACi as anticancer agents is not new and some of these agents (phenylbutyrate, suberoylanilide hydroxamic acid, MS-275, and depsipeptide) are currently included in Phase I/II clinical trials for the treatment of solid tumors, lymphomas, and multiple myeloma (Refs. 29, 30, 31 ; additional information online).8However, the use of these drugs does not allow the achievement of the major goals in cancer therapy: to selectively target anticancer molecules to organs or compartments harboring tumor cells. Conversely, HA-But, which has strong affinity for the CD44 membrane receptor (12) , could be a promising antineoplastic agent for the treatment of primary as well as metastatic intrahepatic cancers, especially taking into consideration that antimetastatic effects have been obtained using a nonoptimal route of administration for the liver (as demonstrated by the limited accumulation observed in distribution analysis); this could mean that it might be possible to administer lower doses of the compound i.v. to obtain a therapeutic effect.


   ACKNOWLEDGMENTS
 
We thank Gabriella Abolafio for technical support in flow cytometry.


   FOOTNOTES
 
Grant support: Ministero dell’Università e della Ricerca Scientifica e Tecnologica, Rome, Italy.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Danila Coradini, Biomolecular Markers of Prognosis and Treatment Response Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy, Phone: 39-02-23903053; Fax: 39-02-23903052; E-mail: danila.coradini{at}istitutotumori.mi.it

8 Internet address: http://clinicaltrials.gov. Back

Received 2/24/04; revised 4/ 9/04; accepted 4/12/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. El-Sera HB Epidemiology of hepatocellular carcinoma. Clin Liver Dis, 5: 87-107, 2001.[CrossRef][Medline]
  2. Linnemann U, Schimanski CC, Gebhardt C, Berger MR Prognostic value of disseminated colorectal tumor cells in the liver: results of follow-up examinations.. Int J Colorectal Dis, 19: 380-6, 2004.[CrossRef][Medline]
  3. Yoshimoto M, Tada T, Saito M, Takahashi K, Uchida Y, Kasumi F Surgical treatment of hepatic metastases from breast cancer. Breast Cancer Res Treat, 59: 177-84, 2000.[CrossRef][Medline]
  4. Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K Liver metastasis at the time of initial diagnosis of lung cancer. Med Oncol, 20: 25-8, 2003.[Medline]
  5. Venook A Treatment of hepatocellular carcinoma: too many options.. J Clin Oncol, 12: 1323-34, 1994.[Abstract/Free Full Text]
  6. Ikeda T, Adachi I, Takashima S, et al A Phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113.JCOG Breast Cancer Study Group. Jpn J Clin Oncol, 29: 23-7, 1999.[Abstract/Free Full Text]
  7. Görg C, Schwerk WB, Wolf M, Havemann K Prognostic value of response to chemotherapy using ultrasound in lung cancer with metastatic liver involvement. Bildgebung, 57: 70-3, 1990.[Medline]
  8. Yamamoto H, Fujimoto J, Okamoto E, Furuyama J, Tamaoki T, Hashimoto-Tamaoki T Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int J Cancer, 76: 897-902, 1998.[CrossRef][Medline]
  9. Velazquez OC, Jabbar A, deMatteo RP, Rombeau JL Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice. Surgery (St. Louis), 120: 440-8, 1996.
  10. Marks PA, Richon VM, Breslow R, Rifkind RA Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol, 13: 477-83, 2001.[CrossRef][Medline]
  11. Coradini D, Pellizzaro C, Abolafio G, et al Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study.. Investig New Drugs, 22: 207-17, 2004.[Medline]
  12. Coradini D, Pellizzaro C, Miglierini G, Daidone MG, Perbellini A Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast cancer cell line.. Int J Cancer, 81: 411-6, 1999.[CrossRef][Medline]
  13. Endo K, Terada T Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression and patient survival.. J Hepatol, 32: 78-84, 2000.[Medline]
  14. Arano Y Recent advances in 99mTc radiopharmaceuticals. Ann Nucl Med, 16: 79-93, 2002.[Medline]
  15. Jurisson SS Tc and Re peptide chemistry Nicolini M Mazzi U eds. . Technetium, rhenium and other metals in chemistry and nuclear medicine, 6th ed. 15-21, SGEditoriali Padova, Italy 2002.
  16. Khatib AM, Kontogiannea M, Fallavollita L, Jamison B, Meteressian S, Brodt P Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res, 59: 1356-61, 1999.[Abstract/Free Full Text]
  17. Asao T, Shibata HR, Batist G, Brodt P Eradication of hepatic metastases of carcinoma H59 by combination chemoimmunotherapy with liposomal muramyl tripeptides-fluorouracil and leucovorin. Cancer Res, 52: 6254-7, 1992.[Abstract/Free Full Text]
  18. Vittori F, Malatesta T, de Notaristefani F The YAP Camera: an accurate gamma-camera particularly suitable for new radiopharmaceuticals research.. IEEE Trans Nucl Sci, 44: 47-53, 1997.
  19. Giron MC, Bello M, Caliceti P, et al YAP-Camera for biodistribution studies in mice of 99mTc-radiotracers Nicolini M Mazzi U eds. . Technetium, rhenium and other metals in chemistry and nuclear medicine, 6th ed. 555-7, SGEditoriali Padova, Italy 2002.
  20. Fu J, Sun X, Zhang ZR Study on of bioadhesive property of carbomer 934 by a gamma camera in vivo. World J Gastroenterol, 8: 176-9, 2002.[Medline]
  21. Rossin R, Blok D, Visentin R, et al 99mTc-labeling experiments on CCK4 by a direct method. Nucl Med Biol, 28: 865-73, 2001.[Medline]
  22. Gustafson S, Bjorknan T, Westlin JE Labelling of high molecular weight hyaluronan with 125-I-tyrosine. Studies in vitro an in vivo in the rat. Glycoconj J, 11: 608-13, 1994.[CrossRef][Medline]
  23. Saegusa S, Shuji I, Kawarada Y Changes in serum hyaluronic acid levels and expression of CD44 and CD44 mRNA in hepatic sinusoidal endothelial cells after major hepatectomy in cirrhotic rats. World J Surg, 26: 694-9, 2002.[Medline]
  24. Laurent TC, Laurent UB, Fraser JR Functions of hyaluronan. Ann Rheum Dis, 54: 429-32, 1995.[Free Full Text]
  25. Mahteme H, Graf W, Larsson BS, Gustafson S Uptake of hyaluronan in hepatic metastases after blocking of liver endothelial cell receptors. Glycoconj J, 15: 935-9, 1998.[CrossRef][Medline]
  26. Carrascal MT, Mendoza L, Valcarcel M, et al Interleukin-18 binding protein reduces B16 melanoma hepatic metastasis in neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res, 63: 491-7, 2003.[Abstract/Free Full Text]
  27. Barbara-Guillem E, Alonso-Varona A, Vidal-Vanaclocha F Selective implantation and growth in rats and mice of experimental liver metastasis in acinar zone one. Cancer Res, 49: 4003-10, 1989.[Abstract/Free Full Text]
  28. Mummert ME, Mummert DI, Ellinger L, Takashima A Functional roles of hyaluronan in B16–F10 melanoma growth and experimental metastasis in mice. Mol Cancer Ther, 2: 295-300, 2003.[Abstract/Free Full Text]
  29. Kelly WK, Richon VM, O’Connor O, et al Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.. Clin Cancer Res, 9: 3578-88, 2003.[Abstract/Free Full Text]
  30. Marshall JL, Rizvi N, Kauh J, et al A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol, 2: 325-32, 2002.[CrossRef][Medline]
  31. Gilbert J, Baker SD, Bowling MK, et al A Phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res, 7: 2292-300, 2001.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Banzato, S. Bobisse, M. Rondina, D. Renier, F. Bettella, G. Esposito, L. Quintieri, L. Melendez-Alafort, U. Mazzi, P. Zanovello, et al.
A Paclitaxel-Hyaluronan Bioconjugate Targeting Ovarian Cancer Affords a Potent In vivo Therapeutic Activity
Clin. Cancer Res., June 1, 2008; 14(11): 3598 - 3606.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coradini, D.
Right arrow Articles by Perbellini, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coradini, D.
Right arrow Articles by Perbellini, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online